Literature DB >> 31938123

Elevated level of Vav1 was correlated with advanced biological behavior and poor prognosis in patients with gastric cancer.

Lili Kang1, Xuwen Hao1, Yanping Tang1, Zhihua Zhao2, Hongjie Zhang2, Yanxia Gong1.   

Abstract

Vav1 play key roles in the progression of human cancer. However, the role of Vav1 in gastric cancer (GC) remains to be elucidated. The present study aimed to investigate the potential relevance of the clinicopathological characteristics and prognostic significance of Vav1 in GC patients.
METHODS: The protein expression of Vav1 was analyzed by immunohistochemistry in formalin-fixed samples obtained from 105 GC patients.
RESULTS: Positive Vav1 expression was correlated with larger tumor size and more lymph node metastasis (P<0.05) in GC tissues. Serosal invasion (hazard ratio [HR] = 2.764, P = 0.007), lymph node metastasis (HR = 1.298, P = 0.002) and Vav1 expression (HR = 0.436, P = 0.006) were identified as independent factors of the overall survival (OS) of GC patients. For advanced GC patients, lymph node metastasis (HR = 1.310, P = 0.003) and Vav1 expression (HR = 0.443, P = 0.010) were the independent prognostic factors of OS.
CONCLUSION: Vav1 performs important functions in the aggressiveness of GC, and Vav1 may serve as a novel prognostic factor in GC. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Stomach; Vav1; cancer; prognosis

Year:  2018        PMID: 31938123      PMCID: PMC6957931     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  2 in total

1.  Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer.

Authors:  Yanting Shen; Huan Xu; Manmei Long; Miaomiao Guo; Peizhang Li; Ming Zhan; Zhong Wang
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

2.  Identification of prognostic alternative splicing events in sarcoma.

Authors:  Hongshuai Li; Jie Yang; Guohui Yang; Jia Ren; Yu Meng; Peiyi Qi; Nan Wang
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.